Frequent fragility of randomized controlled trials for HCC treatment.
Hao ZhangJingtao LiWenting ZengPublished in: BMC cancer (2021)
Many phase 3 RCTs supporting HCC treatments have a low FI, which challenges the confidence in concluding the superiority of these drugs over control treatments.
Keyphrases